Mizuho analyst Joseph Catanzaro initiated coverage of Apogee Therapeutics (APGE) with an Outperform rating and $105 price target The firm believes the company’s APG777 is positioned to play a “significant role” in Th2 inflammatory diseases, namely atopic dermatitis. Phase II readouts in 2026 should validate the drug’s once-quarterly maintenance dosing and “best-in-class” biologic efficacy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Short Report: Fluence Energy short interest at record high
- 3 Best Stocks to Buy Now, 10/17/2025, According to Top Analysts
- Apogee Therapeutics Raises $323.3 Million in Offering
- Buy Recommendation for Apogee Therapeutics: Promising Clinical Developments and Strategic Financial Moves
- Apogee Therapeutics price target lowered to $82 from $87 at BofA